1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
aap Implantate AG

aap Implantate AG

AAQ1.DE
aap Implantate AGDE flagDeutsche Börse
1.61
EUR
-0.13
- -
23.69MMarket Cap
aap Implantate AG
AAQ1.DE
(Deutsche Börse)

Recent

price

1.61

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.27
8.91
7.68
8.16
4.31
3.62
3.08
3.44
3.46
3.66
2.68
2.48
1.93
1.38
1.19
0.9
3.46
Revenue per Share
0.02
0.12
0.71
-0.6
-0.13
-1.56
-2.72
-2.93
-2.46
-6.09
-2.54
-0.55
-0.43
-0.96
-0.35
-0.19
-2.59
Basic EPS, GAAP
-2.03
-0.24
2.09
1.05
-0.85
-0.67
-2.11
-2.14
-2.85
-2.32
-1.18
-0.61
-0.4
-0.4
-0.14
-0.16
-2.39
Free Cash Flow per Basic Share
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.28
2.23
8.73
8.13
8.06
6.43
6.48
3.36
4.75
-0.41
-3.28
-2.48
-2.21
-2.25
-1.74
-1.45
0.6
Book Value per Share
2.56
3.08
2.84
9.6
8.91
8.81
12.8
9.7
6.95
4.89
2.22
2.13
1.8
0.73
0.84
0.49
6.15
Tangible Book Value per Share
3
3
3
3
3
3
3
3
3
3
3
5
6
8
10
14
3
Basic Weighted Avg Shares
28
29
26
28
15
12
10
11
11
12
9
12
12
11
12
12
11
Sales/Revenue/Turnover
2.53
4.3
0.99
7.79
-43.39
-70.67
-94.2
-73.68
-75.82
-63.77
-81.42
-22.12
-29.42
-61.46
-22.27
-20.4
-75.34
Operating Margin (%)
3
3
4
9
2
3
2
2
2
13
3
2
2
4
2
2
2
Depreciation Expense
- -
- -
2
-2
- -
-5
-9
-9
-8
-20
-9
-3
-3
-8
-4
-3
-8
Net Income, GAAP
72.58
36.08
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
0.18
1.34
9.26
-7.4
-3.12
-43.09
-88.39
-85.04
-71.11
-166.28
-94.6
-22.18
-22.26
-69.38
-29.75
-20.7
-74.82
Profit Margin (%)
6
7
11
29
25
25
36
24
15
9
6
7
6
3
4
4
15
Working Capital
- -
- -
2
2
2
1
1
1
- -
2
3
3
1
3
- -
1
- -
LT Debt
45
48
49
47
45
40
55
43
35
19
10
13
13
8
10
9
34
Total Equity
0.41
1.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
2.68
13.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
1.31
6.98
13.05
-7.16
-1.66
-21.54
-42.23
-56.65
-60.25
- -
- -
- -
- -
- -
- -
- -
-188.24
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'18
Mar'19
Jun'19
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
32
29
28

Working Capital

FRC

•

in mil. unless spec.
Dec'18
Mar'19
Jun'19
Total Current Assets
20
17
20
Cash, Cash Equivalents & STI
7
6
8
Accounts Receivable, Net
3
3
2
Inventories
10
9
9
Total Current Liabilities
5
4
5
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.58%
-0.01%
-16.89%
Free Cash Flow
16.65%
-3.08%
48.49%
Net Income, GAAP
21.07%
10.59%
-28.79%
Sales/Revenue/Turnover
1%
6.69%
2.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
3
- -
- -
- -
11
2024
- -
- -
- -
- -
12
2025
- -
- -
- -
- -
12

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.12
- -
- -
- -
-0.96
2024
- -
- -
- -
- -
-0.35
2025
- -
- -
- -
- -
-0.19

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Star Sports Medicine Co., Ltd. (1609.HK)
Broncus Holding Corporation (2216.HK)
FUJIFILM Holdings Corporation (4901.T)
Aplus Biotechnology Corporation Limited (6918.TWO)
Positron Corporation (POSC)
CLASSYS Inc. (214150.KQ)
Business
aap Implantate AG develops, manufactures and markets innovative trauma implants and biomaterials for orthopedics, focusing on the ortho/trauma/spine segment; its core IP-protected portfolio centers on the LOQTEQ anatomical plating system incorporating proprietary locking-compression technology, a comprehensive range of cannulated screws including the HBS screw system, standard plates and screws, and an innovation pipeline featuring antibacterial silver coating technology and resorbierbare magnesium-based implants addressing unmet needs such as infection risk reduction and avoidance of secondary surgeries. Founded in 1990 and headquartered in Berlin, Germany, the company operates globally through direct sales in Germany to hospitals and purchasing groups, a hybrid distribution strategy in the US via its subsidiary aap Implants Inc. in Dover, Delaware, and a network of distributors in around 25 countries across EMEA (52% of sales including strong growth in Spain/Portugal and South Africa), LATAM (Mexico, Brazil, Chile, Peru), and APAC (Thailand, Taiwan, Malaysia, South Korea); wholly-owned subsidiaries include MCTeQ GmbH and MAGIC Implants GmbH in Berlin, with a minority stake in AEQUOS Endoprothetik GmbH. Recent developments include successful completion of a BMBF-funded human clinical trial for its antibacterial silver coating technology in August 2025 with approvals targeted for CE-MDR, FDA and China from 2028, achievement of MDR certification and first product files strengthening European market access, US FDA approval for the HBS screw system, implementation of a January 2024 distribution agreement with a leading global spine and orthopedics company launching LOQTEQ VA Radius System sales in France, multiple equity measures such as cash and non-cash capital increases totaling around EUR 2.6 million in 2024 to boost equity to 66% of total assets and reduce interest-bearing liabilities to EUR 233 thousand, strong sales growth of 15% in Q3 2025 and 6% for FY 2024 to EUR 12.2 million driven by EMEA (+16%), LATAM (+22%) and APAC (+43% in Thailand), extension of CEO Rubino Di Girolamo's contract through 2028, and full admission of all shares to stock exchange trading under ISIN DE000A3H2101 from August 2025 eliminating prior lock-ups.